SEC Form 4 · accession 0001144204-16-095609
Cellectar Biosciences, Inc. · CLRB
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
James V Caruso
Officer — President and CEO · Director
Period of report
Apr 20, 2016
Accepted (ET)
Apr 21, 2016 · 6:00 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001279704
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock, par value $0.00001 per share | Apr 20, 2016 | P | 46,948 | $2.12 | A | 47,548 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Series A Warrants | $3.04 | Apr 20, 2016 | P | 46,948 | A | Apr 20, 2016 | Apr 20, 2021 | Common Stock | 46,948 | 46,948 | D |